Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Down 86.2% in January

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 400 shares, a decrease of 86.2% from the January 15th total of 2,900 shares. Based on an average daily volume of 14,500 shares, the days-to-cover ratio is presently 0.0 days.

Scinai Immunotherapeutics Stock Performance

Scinai Immunotherapeutics stock remained flat at $3.32 during trading hours on Wednesday. 4,012 shares of the company’s stock traded hands, compared to its average volume of 18,425. The stock has a market capitalization of $2.82 million, a PE ratio of -0.01 and a beta of 2.37. The stock has a 50 day moving average of $3.47 and a 200-day moving average of $3.57. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $8.92.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its quarterly earnings data on Friday, November 22nd. The company reported $8.40 EPS for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.